2024
Survival and Therapeutic Outcomes in T-Cell Prolymphocytic Leukemia (T-PLL): A Collaborative Multi-Center Study Cohort
Braunstein Z, McLaughlin E, Lingamaneni P, Barta S, Cao M, Chang T, Ganesan N, Luu B, Mehta-Shah N, Shree T, Watkins M, Zain J, Allen P, Paulino D, Adams B, Wang J, Feng A, Marchi E, Roberts N, Wilcox R, Gutierrez M, Frosch Z, Sklarz T, Sethi T, Foss F, Beaven A, Haverkos B, Treitman R, Stevens P, Mishra A, Stuver R, Hampel P, Brammer J. Survival and Therapeutic Outcomes in T-Cell Prolymphocytic Leukemia (T-PLL): A Collaborative Multi-Center Study Cohort. Blood 2024, 144: 982-982. DOI: 10.1182/blood-2024-194242.Peer-Reviewed Original ResearchT-cell prolymphocytic leukemiaProgression-free survivalOverall survivalMedian OSFrontline treatmentT-PLL patientsTherapeutic outcomesMedian follow-up timeT-cell prolymphocytic leukemia cellsResponse rateCompared to CD4Multi-center seriesVenetoclax-based regimensSecond-line treatmentKaplan-Meier methodFollow-up timeSubgroup survival analysisCox proportional hazards modelsComprehensive clinical dataMulti-center studyProportional hazards modelFrontline therapyNodal involvementResponding patientsT-PLLAsparaginase Treatment Patterns, Toxicity, and Outcomes Among Patients with Extranodal NK/T-Cell Lymphoma: A North American Multicenter Retrospective Cohort Study
Allen P, Bagley E, Graf K, Sethi T, Foss F, Dong N, Saeed H, Wang J, Dittus C, Paulino D, Wilcox R, Barta S, Carvajal V, Mehta-Shah N, Mou E, Ravindra A, Haverkos B, Mehta A, Shea L, Zain J, Reef D, Ayzman A, Greenwell I. Asparaginase Treatment Patterns, Toxicity, and Outcomes Among Patients with Extranodal NK/T-Cell Lymphoma: A North American Multicenter Retrospective Cohort Study. Blood 2024, 144: 1690. DOI: 10.1182/blood-2024-211424.Peer-Reviewed Original ResearchExtranodal NK/T-cell lymphomaNK/T-cell lymphomaAsparaginase useENKTL patientsResponse rateTreatment patternsDiscontinued due to toxicityMulticenter retrospective cohort studyNon-ASP groupAssociated with significant ratesTherapy related deathsEBV-associated lymphomasKaplan-Meier methodCox proportional hazards regressionRetrospective cohort studyQuarter of patientsProportional hazards regressionStatistically significant advantageHigh response rateLimitations of therapyAnalysis of outcomesAssociated lymphomaChemotherapy backboneNeutropenic feverAsparaginase doses
2016
Differences in outcome of patients with syncytial variant Hodgkin lymphoma compared with typical nodular sclerosis Hodgkin lymphoma
Sethi T, Nguyen V, Li S, Morgan D, Greer J, Reddy N. Differences in outcome of patients with syncytial variant Hodgkin lymphoma compared with typical nodular sclerosis Hodgkin lymphoma. Therapeutic Advances In Hematology 2016, 8: 13-20. PMID: 28042455, PMCID: PMC5167078, DOI: 10.1177/2040620716676256.Peer-Reviewed Original ResearchProgression-free survivalNodular sclerosis Hodgkin lymphomaSyncytial variantOverall survivalHodgkin's lymphomaSV patientsComplete responseSV groupShorter progression-free survivalMedian overall survivalOutcomes of patientsPoor-risk groupLower CR rateInstitutional review board approvalKaplan-Meier methodSmall case seriesLog-rank testClassical HL patientsReview board approvalAdvanced diseaseInduction regimenAdult patientsClinical characteristicsHL patientsAggressive course
2015
Differences in Outcome of Patients with Syncytial Variant Hodgkin Lymphoma (HL) Compared with Typical Nodular Sclerosis HL
Sethi T, Nguyen V, Li S, Morgan D, Greer J, Reddy N. Differences in Outcome of Patients with Syncytial Variant Hodgkin Lymphoma (HL) Compared with Typical Nodular Sclerosis HL. Blood 2015, 126: 1441. DOI: 10.1182/blood.v126.23.1441.1441.Peer-Reviewed Original ResearchNodular sclerosis Hodgkin lymphomaProgression-free survivalOutcomes of patientsAdvanced stage diseaseOverall survivalComplete responseHodgkin's lymphomaB symptomsStage diseaseSV groupAchievement of CRInferior progression-free survivalMedian progression-free survivalHodgkin/Reed-Sternberg cellsInstitutional IRB approvalMedian overall survivalStandard ABVD chemotherapyStandard salvage regimensHigh-dose therapyKaplan-Meier methodOnly independent predictorStem cell transplantStage of diseaseCompletion of treatmentNew immunomodulatory agentsInterim Absolute Lymphocyte Count (ALC) As a Predictor of Survival in Hodgkin Lymphoma
Sethi T, Nguyen V, Morgan D, Greer J, Reddy N. Interim Absolute Lymphocyte Count (ALC) As a Predictor of Survival in Hodgkin Lymphoma. Blood 2015, 126: 2640. DOI: 10.1182/blood.v126.23.2640.2640.Peer-Reviewed Original ResearchProgression-free survivalAbsolute lymphocyte countClassical Hodgkin lymphomaNodular sclerosis Hodgkin lymphomaSuperior progression-free survivalOverall survivalHodgkin's lymphomaLymphocyte countAdvanced-stage Hodgkin lymphomaMixed cellularity Hodgkin's lymphomaCompletion of chemotherapyInitial chemotherapy treatmentMedian overall survivalAdvanced stage diseaseCompletion of therapyFirst-line chemotherapyStage Hodgkin lymphomaKaplan-Meier methodPredictors of survivalImmune effector cellsLog-rank testTime of apheresisNew therapeutic agentsTerms of histologyALC recovery